New Options in Anticoagulation for Atrial Fibrillation
The presence of atrial fibrillation significantly increases the risk and burden of thromboembolic stroke. 1 Warfarin is the reference standard treatment for the primary prevention of embolic stroke during atrial fibrillation. 2 However, the long-term use of warfarin has its limitations. Although gui...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2011-09, Vol.365 (10), p.952-953 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 953 |
|---|---|
| container_issue | 10 |
| container_start_page | 952 |
| container_title | The New England journal of medicine |
| container_volume | 365 |
| creator | del Zoppo, Gregory J Eliasziw, Misha |
| description | The presence of atrial fibrillation significantly increases the risk and burden of thromboembolic stroke.
1
Warfarin is the reference standard treatment for the primary prevention of embolic stroke during atrial fibrillation.
2
However, the long-term use of warfarin has its limitations. Although guidelines suggest a target international normalized ratio (INR) of 2.5 (range, 2.0 to 3.0) for this indication,
2
only about 60% of patients have an INR within the recommended range at a given time in usual clinical practice. This is the reason that is most often given for the search for other oral antithrombotic agents that could be simpler to manage . . . |
| doi_str_mv | 10.1056/NEJMe1107516 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_888193747</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2446875531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-a435fab24ee27c6f2bc35457ad2430ce674fdc2c9d002f1745b3b277f6cc45863</originalsourceid><addsrcrecordid>eNptkEtLxDAURoMoTh3duZYiLq3mnXY5DDM-GGc2ug5pmkhKXyYt4r-3Q0dx4d1c-Dh893IAuETwDkHG77er5xeDEBQM8SMQIUZIQinkxyCCEKcJFRmZgbMQSjgOotkpmGGUEphxGAG-NZ_xrutd24TYNfGi6Z1u1ftQqX0W29bHi947VcVrl3tXTfk5OLGqCubisOfgbb16XT4mm93D03KxSTRFuE8UJcyqHFNjsNDc4lwTRplQBaYEasMFtYXGOivGVy0SlOUkx0JYrjVlKSdzcD31dr79GEzoZdkOvhlPyjRNUUYEFSN0O0HatyF4Y2XnXa38l0RQ7h3Jv45G_OrQOeS1KX7hHykjcDMBdR1kY8r6_55vqIZrAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>888193747</pqid></control><display><type>article</type><title>New Options in Anticoagulation for Atrial Fibrillation</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>del Zoppo, Gregory J ; Eliasziw, Misha</creator><creatorcontrib>del Zoppo, Gregory J ; Eliasziw, Misha</creatorcontrib><description>The presence of atrial fibrillation significantly increases the risk and burden of thromboembolic stroke.
1
Warfarin is the reference standard treatment for the primary prevention of embolic stroke during atrial fibrillation.
2
However, the long-term use of warfarin has its limitations. Although guidelines suggest a target international normalized ratio (INR) of 2.5 (range, 2.0 to 3.0) for this indication,
2
only about 60% of patients have an INR within the recommended range at a given time in usual clinical practice. This is the reason that is most often given for the search for other oral antithrombotic agents that could be simpler to manage . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe1107516</identifier><identifier>PMID: 21830960</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Anticoagulants ; Anticoagulants - therapeutic use ; Atrial Fibrillation - drug therapy ; Benzimidazoles - therapeutic use ; beta-Alanine - analogs & derivatives ; beta-Alanine - therapeutic use ; Cardiac arrhythmia ; Dabigatran ; Drug dosages ; Embolisms ; Fibrillation ; Hemorrhage ; Humans ; Intention to Treat Analysis ; Intracranial Hemorrhages - chemically induced ; Morpholines - therapeutic use ; Rivaroxaban ; Stroke ; Thiophenes - therapeutic use ; Thromboembolism ; Warfarin ; Warfarin - therapeutic use</subject><ispartof>The New England journal of medicine, 2011-09, Vol.365 (10), p.952-953</ispartof><rights>Copyright © 2011 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-a435fab24ee27c6f2bc35457ad2430ce674fdc2c9d002f1745b3b277f6cc45863</citedby><cites>FETCH-LOGICAL-c412t-a435fab24ee27c6f2bc35457ad2430ce674fdc2c9d002f1745b3b277f6cc45863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe1107516$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMe1107516$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21830960$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>del Zoppo, Gregory J</creatorcontrib><creatorcontrib>Eliasziw, Misha</creatorcontrib><title>New Options in Anticoagulation for Atrial Fibrillation</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The presence of atrial fibrillation significantly increases the risk and burden of thromboembolic stroke.
1
Warfarin is the reference standard treatment for the primary prevention of embolic stroke during atrial fibrillation.
2
However, the long-term use of warfarin has its limitations. Although guidelines suggest a target international normalized ratio (INR) of 2.5 (range, 2.0 to 3.0) for this indication,
2
only about 60% of patients have an INR within the recommended range at a given time in usual clinical practice. This is the reason that is most often given for the search for other oral antithrombotic agents that could be simpler to manage . . .</description><subject>Anticoagulants</subject><subject>Anticoagulants - therapeutic use</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Benzimidazoles - therapeutic use</subject><subject>beta-Alanine - analogs & derivatives</subject><subject>beta-Alanine - therapeutic use</subject><subject>Cardiac arrhythmia</subject><subject>Dabigatran</subject><subject>Drug dosages</subject><subject>Embolisms</subject><subject>Fibrillation</subject><subject>Hemorrhage</subject><subject>Humans</subject><subject>Intention to Treat Analysis</subject><subject>Intracranial Hemorrhages - chemically induced</subject><subject>Morpholines - therapeutic use</subject><subject>Rivaroxaban</subject><subject>Stroke</subject><subject>Thiophenes - therapeutic use</subject><subject>Thromboembolism</subject><subject>Warfarin</subject><subject>Warfarin - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkEtLxDAURoMoTh3duZYiLq3mnXY5DDM-GGc2ug5pmkhKXyYt4r-3Q0dx4d1c-Dh893IAuETwDkHG77er5xeDEBQM8SMQIUZIQinkxyCCEKcJFRmZgbMQSjgOotkpmGGUEphxGAG-NZ_xrutd24TYNfGi6Z1u1ftQqX0W29bHi947VcVrl3tXTfk5OLGqCubisOfgbb16XT4mm93D03KxSTRFuE8UJcyqHFNjsNDc4lwTRplQBaYEasMFtYXGOivGVy0SlOUkx0JYrjVlKSdzcD31dr79GEzoZdkOvhlPyjRNUUYEFSN0O0HatyF4Y2XnXa38l0RQ7h3Jv45G_OrQOeS1KX7hHykjcDMBdR1kY8r6_55vqIZrAQ</recordid><startdate>20110908</startdate><enddate>20110908</enddate><creator>del Zoppo, Gregory J</creator><creator>Eliasziw, Misha</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20110908</creationdate><title>New Options in Anticoagulation for Atrial Fibrillation</title><author>del Zoppo, Gregory J ; Eliasziw, Misha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-a435fab24ee27c6f2bc35457ad2430ce674fdc2c9d002f1745b3b277f6cc45863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Anticoagulants</topic><topic>Anticoagulants - therapeutic use</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Benzimidazoles - therapeutic use</topic><topic>beta-Alanine - analogs & derivatives</topic><topic>beta-Alanine - therapeutic use</topic><topic>Cardiac arrhythmia</topic><topic>Dabigatran</topic><topic>Drug dosages</topic><topic>Embolisms</topic><topic>Fibrillation</topic><topic>Hemorrhage</topic><topic>Humans</topic><topic>Intention to Treat Analysis</topic><topic>Intracranial Hemorrhages - chemically induced</topic><topic>Morpholines - therapeutic use</topic><topic>Rivaroxaban</topic><topic>Stroke</topic><topic>Thiophenes - therapeutic use</topic><topic>Thromboembolism</topic><topic>Warfarin</topic><topic>Warfarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>del Zoppo, Gregory J</creatorcontrib><creatorcontrib>Eliasziw, Misha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>del Zoppo, Gregory J</au><au>Eliasziw, Misha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Options in Anticoagulation for Atrial Fibrillation</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2011-09-08</date><risdate>2011</risdate><volume>365</volume><issue>10</issue><spage>952</spage><epage>953</epage><pages>952-953</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>The presence of atrial fibrillation significantly increases the risk and burden of thromboembolic stroke.
1
Warfarin is the reference standard treatment for the primary prevention of embolic stroke during atrial fibrillation.
2
However, the long-term use of warfarin has its limitations. Although guidelines suggest a target international normalized ratio (INR) of 2.5 (range, 2.0 to 3.0) for this indication,
2
only about 60% of patients have an INR within the recommended range at a given time in usual clinical practice. This is the reason that is most often given for the search for other oral antithrombotic agents that could be simpler to manage . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>21830960</pmid><doi>10.1056/NEJMe1107516</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2011-09, Vol.365 (10), p.952-953 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_888193747 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Anticoagulants Anticoagulants - therapeutic use Atrial Fibrillation - drug therapy Benzimidazoles - therapeutic use beta-Alanine - analogs & derivatives beta-Alanine - therapeutic use Cardiac arrhythmia Dabigatran Drug dosages Embolisms Fibrillation Hemorrhage Humans Intention to Treat Analysis Intracranial Hemorrhages - chemically induced Morpholines - therapeutic use Rivaroxaban Stroke Thiophenes - therapeutic use Thromboembolism Warfarin Warfarin - therapeutic use |
| title | New Options in Anticoagulation for Atrial Fibrillation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T07%3A19%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Options%20in%20Anticoagulation%20for%20Atrial%20Fibrillation&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=del%20Zoppo,%20Gregory%20J&rft.date=2011-09-08&rft.volume=365&rft.issue=10&rft.spage=952&rft.epage=953&rft.pages=952-953&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe1107516&rft_dat=%3Cproquest_cross%3E2446875531%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=888193747&rft_id=info:pmid/21830960&rfr_iscdi=true |